HighTower Advisors LLC Purchases 2,386 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

HighTower Advisors LLC raised its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,912 shares of the biopharmaceutical company’s stock after purchasing an additional 2,386 shares during the period. HighTower Advisors LLC’s holdings in TG Therapeutics were worth $449,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in TGTX. Bleakley Financial Group LLC purchased a new position in TG Therapeutics during the 4th quarter valued at about $245,000. Castellan Group bought a new position in TG Therapeutics in the fourth quarter worth about $8,539,000. Barclays PLC lifted its position in shares of TG Therapeutics by 83.9% during the third quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after acquiring an additional 270,286 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new stake in TG Therapeutics in the third quarter valued at approximately $2,358,000. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Down 0.8 %

Shares of TGTX opened at $39.86 on Monday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $43.32. The stock’s 50-day moving average price is $34.37 and its 200-day moving average price is $30.39. The company has a market capitalization of $6.26 billion, a price-to-earnings ratio of -398.56 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.07. The business had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares in the company, valued at $18,847,231.83. This represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.